Imexpharm, a leading pharmaceutical company in Vietnam, made a strong impression on international investors at a prestigious C-level Forum took place on August 28-29, 2024 in Shanghai.
During the two-day event organized by Haitong Securities, Imexpharm's representatives presented the company's robust growth trajectory and market leadership in the Vietnamese pharmaceutical industry. Investors were particularly impressed by Imexpharm's consistent financial performance, with revenue and EBITDA experiencing impressive CAGR of 25% and 26% respectively over 2021-2023.
During 1H24, Imexpharm continued to reinforce its strong position in the ETC channel and its leading role in the production and distribution of antibiotics in Vietnam. Investors showed strong interest in the company and expected to visit its factories in the coming time.
Imexpharm's stock price (IMP) experienced a notable increase, closing at 93,900 VND per share on September 4, 2024. This represents a 6.95% increase compared to the previous trading session. The company's market capitalization also saw a substantial rise, reaching over 7.23 trillion VND, marking an 85% increase from the end of last year.
The positive investor sentiment reflects Imexpharm's successful showcasing of its strong financial performance, strategic positioning, and growth potential as the company continues to expand its operations and explore new opportunities.